Search for: "INNOVATION HEALTH HOLDINGS, LLC" Results 1 - 20 of 175
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
26 Apr 2018, 8:54 am by jabboud
This afternoon we are holding a World IP Day program on Capitol Hill featuring three of today’s remarkable female innovators. [read post]
6 Jul 2022, 6:32 am by Alden Abbott
Neapco Holdings LLC, the Supreme Court has in essence told the patent community to “deal with it. [read post]
18 Jul 2014, 11:55 am
June. 13, 2013), holding essentially that, since those meanies on the United States Supreme Court aren’t letting plaintiffs sue generic manufacturers, we’ll change Alabama common law and let them sue someone else. [read post]
24 Apr 2019, 1:55 pm by Alex Moss
For example, courts rejected a patent in DietGoal Innovations LLC v. [read post]
20 Nov 2008, 8:29 pm
Alex Brill is CEO of Matrix Global Advisors, LLC, and a research fellow at the American Enterprise Institute. [read post]
24 Mar 2017, 8:00 am by Schachtman
David Schwartz, of Innovative Science Solutions, LLC. [read post]
13 Feb 2023, 5:59 am by Kevin LaCroix
[i] The P3 Health Group litigation was commenced by a minority owner of P3 Health Group Holdings, LLC (“P3”), Hudson Vegas Investments, LLC (“Hudson”), which challenged P3’s de-SPAC merger. [read post]
20 Feb 2012, 2:38 am by sally
Court of Appeal (Civil Division) Crawford & Anor v Suffolk Mental Health Partnership NHS Trust [2012] EWCA Civ 138 (17 February 2012) Oxford City Council v Basey [2012] EWCA Civ 115 (15 February 2012) High Court (Queen’s Bench Division) AB & Anor v Home Office [2012] EWHC 226 (QB) (16 February 2012) Gold & Anor v Cox & Anor [2012] EWHC 272 (QB) (17 February 2012) Independent Police Complaints Commission v Warner & Ors [2012] EWHC 271 (QB) (17 February 2012) … [read post]
3 Mar 2014, 2:00 pm by Rebecca Jeschke
In December, EFF filed a brief in Octane Fitness, LLC v. [read post]
16 Apr 2024, 8:42 am by Holman
Pharmaceutical innovators are voicing concern that these disclosures are increasingly being used as prior art to invalidate patents arising out of, or otherwise relating to, these trials, in a manner that threatens to disincentivize investment in pharmaceutical innovation. [read post]